Lupin Secures US FDA Approval for Diazepam Injection

Lupin Limited has received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Diazepam Injection, USP, 10 mg/2 mL (5 mg/mL).

USD 77.9 million is the estimated annual market size for this product in the United States.

Reader Takeaway: FDA approval is a positive step for U.S. market expansion; competition will determine revenue impact.

What just happened

Lupin Limited announced that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Diazepam Injection, USP, 10 mg/2 mL (5 mg/mL). This product is presented in single-dose prefilled syringes.

Why this matters

This approval allows Lupin to enter the U.S. market with a generic version of Valium Injection, manufactured by Hoffman-LaRoche, Inc. The drug is used for managing anxiety disorders or providing short-term relief of anxiety symptoms. The U.S. market for this specific product segment is estimated at USD 77.9 million annually, based on IQVIA MAT May 2026 data. This expansion strengthens Lupin's presence in the U.S. market and the central nervous system therapeutic area.

The backstory

Lupin has a global operational footprint with presence in over 100 markets, supported by 15 manufacturing sites and 7 research centers. The company employs over 24,000 professionals. This infrastructure supports its development and distribution of products across various therapy areas.

What changes now

The company can now launch and market Diazepam Injection, USP, in the United States. This approval signifies a successful regulatory milestone and adds to Lupin's generic product portfolio.

Risks to watch

Investors should monitor the launch timeline and the competitive landscape for this product, as these factors will influence its actual revenue contribution.

Peer comparison

Lupin competes in the highly competitive U.S. generics market against numerous global and domestic pharmaceutical companies. Approvals for injectable generic products are a common strategy for many large pharmaceutical players.

Context metrics (time-bound)

• Market Size: USD 77.9 million (Annual, IQVIA MAT May 2026)
• Approval Date: Recent, as per the filing.

What to track next

Investors should watch for Lupin's announcement regarding the commercial launch of the Diazepam Injection and its initial sales performance.